Objective: To evaluate whether GLP-1 RA use added to statins is associated with lower all-cause mortality, myocardial infarction (MI), and ischemic stroke versus statin monotherapy in ASCVD patients with body mass index (BMI) 30 kg/m2. Approach and Results:Using the TriNetX Research Network (108 U.S. healthcare organizations), we identified ASCVD patients with BMI 30 kg/m2 on statins initiating a GLP-1 RA (n=166,278) versus statin-only controls (n=920,176).